IBA signs contract with partner CGN Medical Technology for the installation of a Proteus®PLUS system in China
13 Juni 2023 - 7:00AM
IBA signs contract with partner CGN Medical Technology for the
installation of a Proteus®PLUS system in China
This contract is the second order from CGN
Medical Technology for IBA’s Proteus®PLUS system
Louvain-La-Neuve, Belgium, June 13, 2023
– IBA (Ion Beam Applications S.A., EURONEXT), the world
leader in particle accelerator technology and the world’s leading
provider of proton therapy solutions for the treatment of cancer,
today announced it has signed an equipment contract with its
partner CGN Medical Technology (CGNMT) for IBA’s Proteus®PLUS1
proton therapy system, with one gantry treatment room to be
installed at the West China International Cancer Treatment Center
in Chengdu, Sichuan Province.
CGNMT is the sole proton therapy system vendor
for West China International Cancer Treatment Center in Chengdu.
Following the strategic licensing agreement signed between IBA and
CGNNT in 2020, IBA provides the key components of the Proteus®PLUS
system to CGNMT which will be installed at the hospital site. CGNMT
will be responsible for the installation, commissioning, service
and maintenance of the proton therapy
equipment.
Olivier Legrain, Chief Executive Officer of IBA,
commented: “This project is the ninth Proteus®PLUS system
to be installed in China and the second order received from CGNMT
since the beginning of our successful collaboration. We were happy
to meet the management team of CGNMT in person for the first time
since the pandemic and the signature of our agreement. We have been
impressed with the progress that has been made so far by our
partner and look forward to continuing our relationship with them
to ensure the future success and expansion of proton therapy in the
Chinese market.”
HU Dongming, Chairman of CGN Nuclear
Technology Development Co., Ltd., added: “We were happy to
welcome Mr. Legrain and his team to CGN in Shenzhen and celebrate
the fantastic progress we have made in the delivery of this
innovative technology to the Chinese market. We are pleased and
honored to be working with the West China International Cancer
Treatment Center which demonstrates the potential of our
collaboration for the benefit of cancer patients in China. We look
forward to strengthening our relationship with IBA as we continue
with this project.”
***ENDS*** [1] Proteus®PLUS is a brand
name of Proteus®235
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 1,800 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
About CGNNT
CGNNT (stock code: 000881.SZ) is a leading
company in the nuclear technology application industry that was
restructured and listed in Shenzhen Stock Exchange on February 27,
2017, after the major asset restructuring of CGN Nuclear Technology
Application Co., Ltd. and China Dalian International Cobusiness
(Group) Holdings Ltd. Up to now, CGNNT has completed the layout of
core business units such as accelerator manufacturing, application
development and technical service and modified polymer material.
Their market share leads the nation. CGNNT mainly incubates such
emerging services as radiation detection and security inspection
(managed) and new irradiation application, and actively expands to
high-end fields such as nuclear medicine (especially PT field),
nuclear agricultural science and nuclear environmental protection,
with market size firmly ahead in China.
More information can be found at: http://www.cgnnt.com.cn
CONTACTSSoumya
ChandramouliChief Financial Officer+32 10
475 890Investorrelations@iba-group.com
Olivier LechienCorporate
Communication Director+32 10 475 890communication@iba-group.com
Consilium Strategic
CommunicationsAmber Fennell, Matthew Neal, Lucy
Featherstone+44 (0) 20 3709 5700IBA@consilium-comms.com
1 Proteus®PLUS is a brand name of Proteus®235
- 230613-IBA-ProteusPLUS-1room-EN
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
Von Mai 2023 bis Mai 2024